In yesterday’s Wall Street session, Ocugen Inc (NASDAQ:OCGN) shares traded at $1.64, down -7.87% from the previous session.
OCGN stock price is now 89.84% away from the 50-day moving average and 189.86% away from the 200-day moving average. The market capitalization of the company currently stands at $420.66M.
With the price target maintained at $3.50, Chardan Capital Markets recently Upgraded its rating from Neutral to Buy for Ocugen Inc (NASDAQ: OCGN). On August 23, 2022, Mizuho recently initiated its ‘Buy’ rating on the stock quoting a target price of $5, while ‘ROTH Capital’ rates the stock as ‘Buy’
In other news, Zhang Junge, Director bought 200,278 shares of the company’s stock on Jun 14 ’23. The stock was bought for $99,999 at an average price of $0.50. Upon completion of the transaction, the Director now directly owns 1,077,182 shares in the company, valued at $1.77 million. A total of 2.20% of the company’s stock is owned by insiders.
During the past 12 months, Ocugen Inc has had a low of $0.34 and a high of $2.11. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 5.08, and a quick ratio of 5.08. The fifty day moving average price for OCGN is $0.8863 and a two-hundred day moving average price translates $0.5718 for the stock.
The latest earnings results from Ocugen Inc (NASDAQ: OCGN) was released for Sep, 2023.
Ocugen Inc(OCGN) Company Profile
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
